Search for dissertations about: "Haematological toxicity"

Showing result 1 - 5 of 10 swedish dissertations containing the words Haematological toxicity.

  2. 1. Integrating Efficacy and Toxicity in Preclinical Anticancer Drug Development : Methods and Applications

    Author : Caroline Haglund; Elin Lindhagen; Rolf Larsson; Anna Åleskog; Sigurd Vitols; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Anticancer drugs; In vitro assays; Toxicity testing; Haematological toxicity; Primary tumour cells; Species difference; Clinical pharmacology; Klinisk farmakologi; Clinical Pharmacology; Klinisk farmakologi;

    Abstract : Preclinical testing is an important part of cancer drug development. The aim of this thesis was to establish and evaluate preclinical in vitro methods useful in the development of new anticancer drugs. In paper I, the development of non-clonogenic assays (FMCA-GM) using CD34+ stem cells for assessment of haematological toxicity was described. READ MORE

  4. 2. Individually Tailored Toxicity-based Chemotherapy : Studies on Patients with Primary and Metastatic Breast Cancer

    Author : Henrik Lindman; Jonas Bergh; Carl Blomqvist; Peter Nygren; Bo Nordenskjöld; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; breast cancer; tailored chemotherapy; toxicity-based dosing; high-dose therapy; MR imaging; G-CSF; epirubicin; docetaxel; cyclophosphamide; 5-fluorouracil; Onkologi; Oncology; Onkologi;

    Abstract : Standard dosing of chemotherapy based on body surface area (BSA) results in large individual differences in toxicity due to a large inter-patient variability in pharmacokinetics (PK) and pharmacodynamics (PD). This results in under-dosing in certain patients with a potentially weaker antitumoral effect. READ MORE

  5. 3. Pharmacokinetic-Pharmacodynamic Modelling of Anticancer Drugs : Haematological Toxicity and Tumour Response in Hollow Fibres

    Author : Lena E Friberg; Mats Karlsson; Alan Boddy; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics Pharmacotherapy; Farmakokinetik Farmakoterapi; PHARMACY; FARMACI; farmakokinetik och läkemedelsterapi; Pharmacokinetics and Drug Therapy;

    Abstract : Established quantitative relationships between dose, plasma concentrations and response [pharmacokinetic-pharmacodynamic (PKPD) models] have a high potential in improving therapeutic indices of anticancer drug therapy and in increasing drug development efficiency. PKPD modelling is a helpful tool for characterising and understanding schedule dependence. READ MORE

  6. 4. Targeted radionuclide therapy for patients with neuroendocrine tumours with focus on normal tissue response in 177-Lu-DOTATATE treatment

    Author : Johanna Svensson; Göteborgs universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Radionuclide therapy; Neuroendocrine tumours; 177Lu-DOTATATE; dosimetry; normal tissue response;

    Abstract : Targeted radionuclide therapy with 177Lu-DOTATATE for patients with neuroendocrine tumours utilises the frequent overexpressing of somatostatin receptors on the tumour cells. This treatment modality has demonstrated valuable patient benefits and is well tolerated. However, renal and bone marrow toxicity can become dose limiting and persisting. READ MORE

  7. 5. Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment

    Author : Peter Hovstadius; Rolf Larsson; Elin Lindhagen; Martin Höglund; Sigurd Vitols; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Clinical drug development; CHS 828; Cyanoguanidines; Oncology; Clinical Drug Development; Klinisk läkemedelsutveckling; Pharmaceutical chemistry; Läkemedelskemi;

    Abstract : CHS 828 is a cyanoguanidine with anti-tumour properties which has shown promising effects in several preclinical models. This thesis describes both preclinical and clinical studies aiming to investigate disease specific activity, clinical tolerability and efficacy of CHS 828. READ MORE